欢迎您访问《中华养生保健》官方网站!

中华养生保健 ›› 2022, Vol. 40 ›› Issue (1): 3-5.

• 论著 • 上一篇    下一篇

健脾润燥通络方加减治疗脾虚络阻型原发性干燥综合征的临床疗效

张青   

  1. 平原县第一人民医院中医内科,山东 德州,253100
  • 出版日期:2022-01-01 发布日期:2022-05-13
  • 作者简介:张青(1969.3-),女,汉族,籍贯:山东省德州市,本科,副主任医师,研究方向:中医内科疾病诊疗。

Clinical Effect of Jianpi Runzao Tongluo Decoction on Primary Sjogren’s Syndrome of Spleen Deficiency and Collateral Obstruction

ZHANG Qing   

  1. Department of Traditional Chinese Medicine, First People’s Hospital of Pingyuan County, Shandong Dezhou, 253100, China
  • Online:2022-01-01 Published:2022-05-13

摘要: 目的 分析健脾润燥通络方加减治疗脾虚络阻型原发性干燥综合征的临床疗效。方法 选取2019年1月~2020年10月平原县第一人民医院收治的100例脾虚络阻型原发性干燥综合征患者进行回顾性分析。根据治疗方法的不同分为观察组(采取健脾润燥通络方加减治疗,共计50例)和对照组(采取常规西药治疗,共计50例)。比较两组患者临床疗效、治疗前后中医证候积分以及疾病活动指数的差异,并统计两组患者治疗期间不良反应发生率的差异。结果 观察组患者临床疗效明显高于对照组(P<0.05);观察组治疗前后中医证候积分以及疾病活动指数改善幅度明显高于对照组(P<0.05);观察组治疗期间不良反应发生率明显低于对照组(P<0.05)。结论 健脾润燥通络方相比于常规西药治疗具有更高的疗效与安全性,能够有效改善干燥综合征患者的临床症状,有临床应用价值。

关键词: 健脾润燥通络方, 原发性干燥综合征, 临床疗效

Abstract: Objective To analyze the clinical efficacy of Jianpi Runzao Tongluo Decoction in treating primary Sjogren’s syndrome with spleen deficiency and collateral obstruction. Methods The clinical data of 100 patients with primary Sjogren’s syndrome of spleen-deficiency and collateral obstruction type were selected from January 2019 to October 2020 for retrospective analysis, and they were divided into the observation group (50 cases were treated with Jianpi Tunzao Tongluo Decoction) and the control group (50 cases were treated with conventional western medicine according to different treatment methods. The clinical efficacy of the two groups and the differences in TCM syndrome scores before and after treatment and the disease activity index were compared, and the differences in the incidence of adverse reactions during the treatment of the two groups were counted. Results The observation group was significantly higher than that of the control group (P<0.05); the improvement of the TCM syndrome score and disease activity index of the observation group before and after treatment was significantly higher than that of the control group (P<0.05); adverse reactions occurred during the treatment of the observation group The rate was significantly lower than that of the control group (P<0.05). Conclusion Compared with conventional western medicine treatment, Jianpi Runzao Tongluo Decoction has higher efficacy and safety, can effectively improve the clinical symptoms of Sjogren’s syndrome, and is worthy of popularization.

Key words: Jianpi Runzao Tongluo Decoction, Primary Sjogren's syndrome, Clinical efficacy

中图分类号: